February 18, 2026
Why Lower Endotoxin Levels Matter: Raising the Bar for Patient Safety and Product Quality
The global pharmaceutical landscape continues to undergo rapid transformation. As the drug pipeline and the need for complex modalities such as biologics, advanced therapies, and mRNA-based treatments grow, the demand for high-quality, contamination-free primary packaging has never been greater. Regulators worldwide are challenging current practices and tightening standards, and patients are increasingly aware of final drug product safety. For pharmaceutical manufacturers, this translates into dual pressures; mitigating risk throughout the drug’s lifecycle and meeting stricter quality expectations to ensure patient safety and confidence.
Haley Johnson
Sr. Manager, Product Management